ReviewTransplant international : official journal of the European Society for Organ Transplantation2023
Cytomegalovirus Cell-Mediated Immunity: Ready for Routine Use?
Review in Transplant international : official journal of the European Society for Organ Transplantation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07570433 (HORUS-Cytomegalovirus Open Proof-of-concept Exploratory Trial), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
HORUS-Cytomegalovirus Open Proof-of-concept Exploratory Trial (HORUS-COPE): An International Proof-of-concept Clinical Trial on Modulation of Immunosuppressive Regimen in Solid-organ Transplant Recipients With Cytomegalovirus Infection.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Antiviral Agents for Preventing Cytomegalovirus Disease in Recipients of Hematopoietic Cell Transplantation.Viruses · 2024Pooled it
- A comparative performance evaluation of the VIDAS cytomegalovirus (CMV) interferon-gamma release assay (IGRA) and T-SPOT CMV for measuring CMV-specific T-cell responses in allogeneic hematopoietic stem cell transplant recipients receiving letermovir prophylaxis.Journal of clinical microbiology · 2026Article
- Mechanisms and Determinants of CMV Reactivation in Kidney Transplantation.International journal of molecular sciences · 2026Review
- Comparison of two IGRA assays exploring cell-mediated immunity against CMV, BKV, and EBV in kidney transplant patients.Microbiology spectrum · 2026Article
- Molecular signatures and causal factors underlying latent cytomegalovirus infection among people living with HIV (PLHIV).Nature communications · 2026Article
- Interpretable SVM Model for Predicting CMV Infection in Seropositive Kidney Transplant Recipients: A Single-Center Retrospective Study.Infection and drug resistance · 2026Article
- A multiparameter whole blood platform for assessment of anti-CMV immunity in allogeneic stem cell transplantation recipients.Frontiers in immunology · 2026Article
- Interactions Between Immunosuppressive Regimens and Cytomegalovirus Infection After Solid-Organ Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2026Review
- Beyond Thresholds: CMV Replication Kinetics as Early Predictors of Clinical Risk in Transplant Recipients.Infection and drug resistance · 2026Review
- Early CMV DNAemia during letermovir prophylaxis predicts lower risk of late CMV infection and is associated with enhanced T-cell immunity after alloHSCT.Scientific reports · 2025Article
- Seeing the Bigger Picture: Incorporating Cytomegalovirus-Specific Cell-Mediated Immunity Into Risk Prediction for Cytomegalovirus.Kidney international reports · 2025Article
- A New Prognostic Score Based on Cell-Mediated Immunity for Cytomegalovirus Infection After Transplantation.Kidney international reports · 2025Article
- Quantifying Gamma-Interferon from CMV-Specific CD8+ T Cells Defines Protection Against Clinically Significant CMV Infection in Solid Organ Transplant Recipients: The Quanti-CMV Score.Microorganisms · 2025Article
- Immune Monitoring Assays: Predicting Cytomegalovirus and Other Infections in Solid Organ Transplant Recipients.Transplantation · 2025Article
- Advancements in Cytomegalovirus Management Among Solid Organ Transplant Recipients: Insights From the ESOT CMV Workshop 2023.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Comparison of four different assays to evaluate cellular-mediated immunity against cytomegalovirus in solid organ transplantation.Frontiers in immunology · 2025Article
- γδ T Cells' Role in Donor-Specific Antibody Generation: Insights From Transplant Recipients and Experimental Models.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Evaluation of T Cell Response to SARS-CoV-2 in Kidney Transplant Recipients Receiving Monoclonal Antibody Prophylaxis and the Utility of a Bivalent mRNA Vaccine Booster Dose.Microorganisms · 2024Article
- Innate and adaptive effector immune drivers of cytomegalovirus disease in lung transplantation: a double-edged sword.Frontiers in transplantation · 2024Review
- Current and emerging tools for simultaneous assessment of infection and rejection risk in transplantation.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Utilizing assays that assess specific T-cell-mediated immunity against cytomegalovirus (CMV) holds the potential to enhance personalized strategies aimed at preventing and treating CMV in organ transplantation. This includes improved risk stratification during transplantation compared to relying solely on CMV serostatus, as well as determining the optimal duration of antiviral prophylaxis, deciding on antiviral therapy when asymptomatic replication occurs, and estimating the risk of recurrence. In this review, we initially provide an overlook of the current concepts into the immune control of CMV after transplantation. We then summarize the existent literature on the clinical experience of the use of immune monitoring in organ transplantation, with a particular interest on the outcomes of interventional trials. Current evidence indicates that cell-mediated immune assays are helpful in identifying patients at low risk for replication for whom preventive measures against CMV can be safely withheld. As more data accumulates from these and other clinical scenarios, it is foreseeable that these assays will likely become part of the routine clinical practice in organ transplantation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.